First Manhattan
UROV

First Manhattan’s Urovant Sciences Ltd. UROV Stock Holding History

First Manhattan’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-229,343
Closed -$2.11M – 1513
2020
Q1 		$2.11M Buy
+229,343
New +$2.76M 0.01% 294

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $957M AUM 44.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return

First Manhattan's UROV Position: Q2 2020 in Review

First Manhattan sold out of Urovant Sciences Ltd. (UROV) in Q2 2020, closing a stake of 229,343 shares — an estimated $2.11M sold.

First Manhattan first reported a position in UROV in Q1 2020 and held it in 1 quarter. The position peaked at $2.11M in Q1 2020. 25 funds tracked by Wall St. Rank hold UROV as of Q2 2020.

  • First Manhattan reported no remaining Urovant Sciences Ltd. position as of Q2 2020 after selling out during the quarter.
  • First Manhattan sold 229,343 Urovant Sciences Ltd. shares in Q2 2020, an estimated $2.11M.
  • First Manhattan first reported a position in Urovant Sciences Ltd. in Q1 2020 and held it in 1 quarter.
  • First Manhattan's Urovant Sciences Ltd. position peaked at $2.11M in Q1 2020.
  • 25 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q2 2020.

Based on First Manhattan's 13F filing for Q2 2020, filed 14 Aug 2020.